Value of prophylaxis vs on‐demand treatment: Application of a value framework in hemophilia
Authors:
- Diane NugentDNDiane Nugent
- Brian O'MAhonyBOBrian O'MAhony
- on behalf of the International Haemophilia Access Strategy CouncilOCon behalf of the International Haemophilia Access Strategy Council
Open Access
- 8 August 2018
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 24 (5) , 755-765
Abstract
Introduction: Therapeutic advances over the past 30 years have led to longer life expectancy and improved quality of life (QOL) for persons with hemophilia. Access to innovative therapy may be compromised if treatment decisions are driven solely by cost. New strategies are needed to assess true therapeutic values, along with financial cost, as physicians, policymakers, payers and manufacturers work together to improve patient care.Aim: To provide an evidence‐based assessment of the value of prophylaxis vs on‐demand therapy for hemophilia, based on a widely recognized three‐tiered value framework approach for assessing a range of therapeutic interventions.Methods: Data from six randomized clinical trials (ESPRIT, Joint Outcomes Study, SPINART, LEOPOLD II, ADVATE and POTTER) and four observational studies comparing primary and secondary prophylaxis vs on‐demand therapy were applied to a hemophilia value framework.Results: Both primary and secondary prophylaxis showed advantages in Tier 1 “Degree of health/recovery” outcomes, including measures of bleeding, musculoskeletal complications, pain, function/activity and QOL. Tier 2 “Process of Recovery” outcomes, also favoured prophylaxis, including measures of recovery time, return to normal activities, orthopaedic intervention and venous access. In Tier 3 “Sustainability of Health Recovery,” measures of breakthrough bleeds, joint preservation, sustained productivity and QOL showed significant improvement with prophylaxis.Conclusion: The hemophilia value framework affirmed value of primary and secondary prophylaxis vs on‐demand therapy, with clinical benefit demonstrated in all three tiers. This analysis also demonstrates clinical utility of the value framework process in the determination of optimal and cost‐effective hemophilia care for all stakeholders.Keywords
Funding Information
- Bayer (NA)
This publication has 19 references indexed in Scilit:
- Guidelines for the management of hemophiliaHaemophilia, 2012
- A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A managementJournal of Thrombosis and Haemostasis, 2012
- A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)Journal of Thrombosis and Haemostasis, 2011
- What Is Value in Health Care?New England Journal of Medicine, 2010
- Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United StatesBritish Journal of Haematology, 2010
- Blood‐induced joint disease: the pathophysiology of hemophilic arthropathyJournal of Thrombosis and Haemostasis, 2010
- Haemophilia care then, now and in the futureHaemophilia, 2008
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- Life expectancy in hemophilia outcomeJournal of Thrombosis and Haemostasis, 2006
- A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacsJournal of Internal Medicine, 1994